These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 27533056)

  • 1. Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART).
    Sahlén A; Varenhorst C; Lagerqvist B; Renlund H; Wallentin L; James SK; Jernberg T
    Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):5-12. PubMed ID: 27533056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Baseline Anemia in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: A Prespecified Analysis From the VALIDATE-SWEDEHEART Trial.
    Wester A; Attar R; Mohammad MA; Andell P; Hofmann R; Jensen J; Szummer K; Erlinge D; Koul S
    J Am Heart Assoc; 2019 Aug; 8(16):e012741. PubMed ID: 31387441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Yudi MB; Clark DJ; Farouque O; Eccleston D; Andrianopoulos N; Duffy SJ; Brennan A; Lefkovits J; Ramchand J; Yip T; Oqueli E; Reid CM; Ajani AE;
    Intern Med J; 2016 May; 46(5):559-65. PubMed ID: 26909472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry.
    Sahlén A; Varenhorst C; Lagerqvist B; Renlund H; Omerovic E; Erlinge D; Wallentin L; James SK; Jernberg T
    Eur Heart J; 2016 Nov; 37(44):3335-3342. PubMed ID: 27436867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ticagrelor immediately prior to stenting is associated with smaller residual thrombus in patients with acute coronary syndrome.
    Abtahian F; Yonetsu T; Vergallo R; Jia H; Kato K; Tian J; Hu S; McNulty I; Jang IK
    Int J Cardiol; 2013 Oct; 168(3):3099-101. PubMed ID: 23642594
    [No Abstract]   [Full Text] [Related]  

  • 6. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.
    Held C; Asenblad N; Bassand JP; Becker RC; Cannon CP; Claeys MJ; Harrington RA; Horrow J; Husted S; James SK; Mahaffey KW; Nicolau JC; Scirica BM; Storey RF; Vintila M; Ycas J; Wallentin L
    J Am Coll Cardiol; 2011 Feb; 57(6):672-84. PubMed ID: 21194870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
    Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
    J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study.
    Bagai A; Peterson ED; Honeycutt E; Effron MB; Cohen DJ; Goodman SG; Anstrom KJ; Gupta A; Messenger JC; Wang TY
    Eur Heart J Acute Cardiovasc Care; 2015 Dec; 4(6):499-508. PubMed ID: 25515725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
    Shimada YJ; Bansilal S; Wiviott SD; Becker RC; Harrington RA; Himmelmann A; Neely B; Husted S; James SK; Katus HA; Lopes RD; Steg PG; Storey RF; Wallentin L; Cannon CP;
    Am Heart J; 2016 Jul; 177():1-8. PubMed ID: 27297843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ticagrelor: a review of its use in adults with acute coronary syndromes.
    Dhillon S
    Am J Cardiovasc Drugs; 2015 Feb; 15(1):51-68. PubMed ID: 25672642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
    Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
    JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Ischemic and Bleeding Risk Scores and the Use of New P2Y
    Flores-Blanco PJ; Cambronero-Sánchez F; Raposeiras-Roubin S; Abu-Assi E; Leithold G; Cobas-Paz R; Rodríguez Serrano AI; Calvo-Iglesias F; Valdés M; Januzzi JL; Iñiguez-Romo A; Manzano-Fernández S
    Rev Esp Cardiol (Engl Ed); 2018 Jul; 71(7):538-544. PubMed ID: 29146484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial.
    Brilakis ES; Held C; Meier B; Cools F; Claeys MJ; Cornel JH; Aylward P; Lewis BS; Weaver D; Brandrup-Wognsen G; Stevens SR; Himmelmann A; Wallentin L; James SK
    Am Heart J; 2013 Sep; 166(3):474-80. PubMed ID: 24016496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Performance of CRUSADE and ACUITY Bleeding Risk Scores in Ticagrelor-Treated ACS Patients Who Underwent PCI.
    Xi S; Zhou S; Wang X; Liu J; Qin L; Liu J; Yin T; Chen Y
    Thromb Haemost; 2017 Nov; 117(11):2186-2193. PubMed ID: 29044298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention.
    Laine M; Toesca R; Berbis J; Frere C; Barnay P; Pansieri M; Peyre JP; Michelet P; Bessereau J; Camilleri E; Helaf O; Camaleonte M; Paganelli F; Dignat-George F; Bonello L
    Thromb Res; 2013 Jul; 132(1):e15-8. PubMed ID: 23726090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Real-World" Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States.
    Larmore C; Effron MB; Molife C; DeKoven M; Zhu Y; Lu J; Karkare S; Lieu HD; Lee WC; Vetrovec GW
    Catheter Cardiovasc Interv; 2016 Oct; 88(4):535-544. PubMed ID: 26577386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New antiplatelet agents in the treatment of acute coronary syndromes.
    Sabouret P; Taiel-Sartral M
    Arch Cardiovasc Dis; 2014 Mar; 107(3):178-87. PubMed ID: 24630752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ticagrelor: Effects Beyond the P2Y
    Sumaya W; Storey RF
    Interv Cardiol Clin; 2017 Jan; 6(1):49-55. PubMed ID: 27886822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.
    Husted S
    Postgrad Med; 2011 Nov; 123(6):79-90. PubMed ID: 22104457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study.
    De Luca L; Leonardi S; Cavallini C; Lucci D; Musumeci G; Caporale R; Abrignani MG; Lupi A; Rakar S; Gulizia MM; Bovenzi FM; De Servi S;
    Eur Heart J Acute Cardiovasc Care; 2015 Oct; 4(5):441-52. PubMed ID: 25414322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.